Aerie Pharmaceuticals Inc (AERI) 21.90 $AERI
Aerie Pharmaceuticals names Dr Benjamin F. McGraw to board
M2 - Tue Oct 07, 7:01AM CDT
Pharmaceutical company Aerie Pharmaceuticals (NasdaqGM:AERI) revealed on Monday the addition of Benjamin F. McGraw, III, PharmD to its board of directors and as a member of its Audit Committee, effective 30 September 2014.
AERI: 21.90 (+0.15)
Aerie Pharmaceuticals Elects Benjamin F. McGraw, III to Its Board of Directors
Business Wire - Mon Oct 06, 3:45PM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that Benjamin F. McGraw, III, Pharm.D., has been elected to the Company's Board of Directors and as a member of the Audit Committee, effective September 30, 2014. Dr. McGraw brings more than 30 years of experience in the life sciences, responsible for advancing breakthrough technologies and numerous development-stage programs through commercialization.
AERI: 21.90 (+0.15)
Aerie Announces Closing of $125 Million Convertible Notes Financing
Business Wire - Tue Sep 30, 3:05PM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it has closed its $125 million financing with Deerfield Management Company L.P. ("Deerfield"
, a current Aerie shareholder. Under the terms of the financing, the notes are secured and will accrue interest at a rate of 1.75% per annum until maturity in September of 2021. The notes are convertible at a conversion price representing a 30% premium over the closing price of Aerie stock on September 8, 2014, resulting in a conversion price of $24.80 per share.
AERI: 21.90 (+0.15)
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - 22 Drug Profiles from 11 Companies
M2 - Fri Sep 12, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c97xhn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Santen Pharmaceutical Co., Ltd. - Oxford BioMedica plc - Sylentis S.A. - Ono Pharmaceutical Co., Ltd. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Amakem NV Drug Profiles - tafluprost - (tafluprost timolol maleate) - latanoprostene bunod - latanoprost - OPC-1085EL - trabodenoson - SYL-040012 - RO-5093151 - latanoprost - AR-13324 - AMA-0076 - ONO-9054 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - latanoprost SR - Glaucoma-GT - ATS-8535 - Small Molecule for Glaucoma For more information visit http://www.researchandmarkets.com/research/c97xhn/openangle
AERI: 21.90 (+0.15)
Aerie expects USD125m from convertible notes financing
M2 - Tue Sep 09, 6:42AM CDT
Pharmaceutical company Aerie Pharmaceuticals (NasdaqGM:AERI) revealed on Tuesday the receipt of a USD125m financing commitment from its current shareholder, Deerfield Management Company.
AERI: 21.90 (+0.15)
Deerfield Management Company Announces a $125 Million Facility with Aerie Pharmaceuticals
Business Wire - Tue Sep 09, 5:03AM CDT
Deerfield Management Company announced today it has committed to invest $125 million in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) through senior secured convertible notes. The financing is expected to be funded before the end of September 2014, subject to customary closing conditions. The facility provides Aerie with capital for the continued advancement of development activities for the Company's clinical-stage product pipeline, general corporate purposes and strategic growth opportunities.
AERI: 21.90 (+0.15)
Aerie Announces $125 Million Convertible Notes
Business Wire - Tue Sep 09, 5:00AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it has received a $125 million financing commitment from Deerfield Management Company L.P. ("Deerfield" , a current Aerie shareholder. The financing is expected to be funded before the end of September 2014, subject to customary closing conditions. Aerie intends to use the proceeds from this financing for the continued advancement of development activities for the Company's clinical-stage product pipeline, general corporate purposes and strategic growth opportunities.
AERI: 21.90 (+0.15)
Aerie Pharmaceuticals to Host Investor Day on September 10, 2014
Business Wire - Thu Sep 04, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that the Company will host a live webcast in conjunction with its Investor Day on Wednesday, September 10, 2014 at 12:00p.m. ET in New York, NY.
AERI: 21.90 (+0.15)
Aerie Pharmaceuticals Inc. Initiates Phase 3 Safety-Only Registration Trial in Canada of Rhopressa(TM) in Patients with Glaucoma
Business Wire - Wed Sep 03, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on August 29, dosing commenced of the first patients enrolled in the Company's Phase 3 registration trial in Canada of Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The study, named "Rocket 3," is designed to evaluate safety and tolerability of Rhopressa(TM) in patients over a 12 month period and is part of a broad Phase 3 program being conducted by Aerie. The Company recently announced the commencement of two Phase 3 trials in the United States, "Rocket 1" and "Rocket 2," which are focused on demonstrating non-inferiority of IOP lowering for Rhopressa(TM) compared to timolol, the most widely used comparator in registration trials for glaucoma. Aerie anticipates total enrollment of approximately 1,300 patients in the three Phase 3 trials of Rhopressa(TM).
AERI: 21.90 (+0.15)
Aerie Pharmaceuticals to Present at the Canaccord Genuity 34th Annual Growth Conference
Business Wire - Thu Aug 07, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer will present at the Canaccord Genuity 34th Annual Growth Conference on Wednesday, August 13, 2014 at 11:30a.m. Eastern Time in Boston, MA. Dr. Anido will provide an Aerie overview and business update.
AERI: 21.90 (+0.15)
Aerie Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Business and Product Development Update
Business Wire - Wed Aug 06, 3:05PM CDT
--After Successful Phase 2b Results, Roclatan(TM) Phase 3 Enabling Activities in Progress
AERI: 21.90 (+0.15)
Aerie Pharmaceuticals, Inc. Receives Health Canada "No Objection Letter" to Commence Phase 3 Registration Trial of Rhopressa(TM) in Patients with Glaucoma in Canada
Business Wire - Thu Jul 24, 6:31AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that it has received a No Objection Letter ("NOL" from Health Canada to conduct a Phase 3 registration trial of Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension in Canada. The study, named "Rocket 3," is designed to evaluate safety and tolerability of Rhopressa(TM) in patients over 12 months and is part of a broad Phase 3 program being conducted by Aerie. The Company recently announced the commencement of two Phase 3 trials in the United States, "Rocket 1" and "Rocket 2," which are focused on demonstrating non-inferiority of IOP lowering for Rhopressa(TM) compared to timolol, the most widely used comparator in registration trials for glaucoma. Aerie anticipates total enrollment of approximately 1,300 patients in the three Phase 3 trials of Rhopressa(TM).
AERI: 21.90 (+0.15)
Aerie Pharmaceuticals to Announce Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 6, 2014
Business Wire - Wed Jul 23, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced today that its second quarter 2014 financial results will be released after the market closes on Wednesday, August 6, 2014. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.
AERI: 21.90 (+0.15)
Aerie Pharmaceuticals Initiates Phase 3 Registration Trials of Rhopressa(TM), Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma
Business Wire - Mon Jul 14, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on July 11, dosing commenced of the first patients enrolled in the Company's Phase 3 registration clinical trials of Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Aerie anticipates total enrollment of approximately 1,300 patients in three Phase 3 registration trials of Rhopressa(TM). The trials will measure efficacy over three months and safety over 12 months. The primary efficacy endpoint of the trials will be to demonstrate non-inferiority of IOP lowering for Rhopressa(TM) compared to timolol. Timolol is the most widely used comparator in registration trials for glaucoma. There will be two trials conducted in the United States, named "Rocket 1" and "Rocket 2," and one safety-only study in Canada, named "Rocket 3."
AERI: 21.90 (+0.15)
Executive Appointments and Technical Updates - Analyst Notes on Aeri Pharmaceuticals, DaVita, Prana Biotechnology, Raptor and Avanir Pharmaceuticals
PR Newswire - Mon Jul 14, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Aeri Pharmaceuticals, Inc. (NASDAQ: AERI), DaVita HealthCare Partners Inc. (NYSE: DVA), Prana Biotechnology Ltd. (NASDAQ: PRAN), Raptor Pharmaceuticals Corp. (NASDAQ: RPTP) and Avanir Pharmaceuticals (NASDAQ: AVNR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4726-100free.
AVNR: 11.80 (+0.01), DVA: 75.67 (+0.17), RPTP: 10.54 (-0.05), AERI: 21.90 (+0.15), PRAN: 1.96 (-0.01)
Aerie Pharmaceuticals, Inc. (AERI) in Focus: Stock up 8.37% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 7:44AM CDT
Aerie Pharmaceuticals, Inc. (AERI) was a big mover last session, as the company saw its shares rise over 8% on the day.
SGYP: 2.83 (-0.02), BCRX: 11.49 (+0.12), AERI: 21.90 (+0.15), OHRP: 7.07 (-0.26)
Weakness Seen in TherapeuticsMD (TXMD): Stock Tumbles 8.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 7:34AM CDT
TherapeuticsMD has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the past one day
SGYP: 2.83 (-0.02), BCRX: 11.49 (+0.12), TXMD: 4.16 (+0.01), AERI: 21.90 (+0.15)
Strength Seen in TherapeuticsMD, Inc. (TXMD): Stock Shoots 32.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:44AM CDT
TherapeuticsMD, Inc. (TXMD) was a big mover last session, as the company saw its shares surge over 32% on the day.
SGYP: 2.83 (-0.02), TXMD: 4.16 (+0.01), AERI: 21.90 (+0.15), OHRP: 7.07 (-0.26)
Why Auxilium Pharmaceuticals (AUXL) Could Be Positioned for a Slump? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:32AM CDT
Auxilium Pharmaceuticals has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
SGYP: 2.83 (-0.02), BCRX: 11.52 (+0.15), AUXL: 30.97 (-0.15), AERI: 21.90 (+0.15)
IntelliPharmaCeutics International (IPCI) Crumbles: Stock Plunges by 13.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:30AM CDT
IntelliPharmaCeutics International has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
SGYP: 2.83 (-0.02), BCRX: 11.52 (+0.15), IPCI: 2.72 (unch), AERI: 21.90 (+0.15)
Aerie Pharmaceuticals names Dr Benjamin F. McGraw to board
M2 - Tue Oct 07, 7:01AM CDT
Pharmaceutical company Aerie Pharmaceuticals (NasdaqGM:AERI) revealed on Monday the addition of Benjamin F. McGraw, III, PharmD to its board of directors and as a member of its Audit Committee, effective 30 September 2014.
AERI: 21.90 (+0.15)
Aerie Pharmaceuticals Elects Benjamin F. McGraw, III to Its Board of Directors
Business Wire - Mon Oct 06, 3:45PM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that Benjamin F. McGraw, III, Pharm.D., has been elected to the Company's Board of Directors and as a member of the Audit Committee, effective September 30, 2014. Dr. McGraw brings more than 30 years of experience in the life sciences, responsible for advancing breakthrough technologies and numerous development-stage programs through commercialization.
AERI: 21.90 (+0.15)
Aerie Announces Closing of $125 Million Convertible Notes Financing
Business Wire - Tue Sep 30, 3:05PM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it has closed its $125 million financing with Deerfield Management Company L.P. ("Deerfield"
, a current Aerie shareholder. Under the terms of the financing, the notes are secured and will accrue interest at a rate of 1.75% per annum until maturity in September of 2021. The notes are convertible at a conversion price representing a 30% premium over the closing price of Aerie stock on September 8, 2014, resulting in a conversion price of $24.80 per share. AERI: 21.90 (+0.15)
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - 22 Drug Profiles from 11 Companies
M2 - Fri Sep 12, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c97xhn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Santen Pharmaceutical Co., Ltd. - Oxford BioMedica plc - Sylentis S.A. - Ono Pharmaceutical Co., Ltd. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Amakem NV Drug Profiles - tafluprost - (tafluprost timolol maleate) - latanoprostene bunod - latanoprost - OPC-1085EL - trabodenoson - SYL-040012 - RO-5093151 - latanoprost - AR-13324 - AMA-0076 - ONO-9054 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - latanoprost SR - Glaucoma-GT - ATS-8535 - Small Molecule for Glaucoma For more information visit http://www.researchandmarkets.com/research/c97xhn/openangle
AERI: 21.90 (+0.15)
Aerie expects USD125m from convertible notes financing
M2 - Tue Sep 09, 6:42AM CDT
Pharmaceutical company Aerie Pharmaceuticals (NasdaqGM:AERI) revealed on Tuesday the receipt of a USD125m financing commitment from its current shareholder, Deerfield Management Company.
AERI: 21.90 (+0.15)
Deerfield Management Company Announces a $125 Million Facility with Aerie Pharmaceuticals
Business Wire - Tue Sep 09, 5:03AM CDT
Deerfield Management Company announced today it has committed to invest $125 million in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) through senior secured convertible notes. The financing is expected to be funded before the end of September 2014, subject to customary closing conditions. The facility provides Aerie with capital for the continued advancement of development activities for the Company's clinical-stage product pipeline, general corporate purposes and strategic growth opportunities.
AERI: 21.90 (+0.15)
Aerie Announces $125 Million Convertible Notes
Business Wire - Tue Sep 09, 5:00AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it has received a $125 million financing commitment from Deerfield Management Company L.P. ("Deerfield"
, a current Aerie shareholder. The financing is expected to be funded before the end of September 2014, subject to customary closing conditions. Aerie intends to use the proceeds from this financing for the continued advancement of development activities for the Company's clinical-stage product pipeline, general corporate purposes and strategic growth opportunities. AERI: 21.90 (+0.15)
Aerie Pharmaceuticals to Host Investor Day on September 10, 2014
Business Wire - Thu Sep 04, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that the Company will host a live webcast in conjunction with its Investor Day on Wednesday, September 10, 2014 at 12:00p.m. ET in New York, NY.
AERI: 21.90 (+0.15)
Aerie Pharmaceuticals Inc. Initiates Phase 3 Safety-Only Registration Trial in Canada of Rhopressa(TM) in Patients with Glaucoma
Business Wire - Wed Sep 03, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on August 29, dosing commenced of the first patients enrolled in the Company's Phase 3 registration trial in Canada of Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The study, named "Rocket 3," is designed to evaluate safety and tolerability of Rhopressa(TM) in patients over a 12 month period and is part of a broad Phase 3 program being conducted by Aerie. The Company recently announced the commencement of two Phase 3 trials in the United States, "Rocket 1" and "Rocket 2," which are focused on demonstrating non-inferiority of IOP lowering for Rhopressa(TM) compared to timolol, the most widely used comparator in registration trials for glaucoma. Aerie anticipates total enrollment of approximately 1,300 patients in the three Phase 3 trials of Rhopressa(TM).
AERI: 21.90 (+0.15)
Aerie Pharmaceuticals to Present at the Canaccord Genuity 34th Annual Growth Conference
Business Wire - Thu Aug 07, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer will present at the Canaccord Genuity 34th Annual Growth Conference on Wednesday, August 13, 2014 at 11:30a.m. Eastern Time in Boston, MA. Dr. Anido will provide an Aerie overview and business update.
AERI: 21.90 (+0.15)
Aerie Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Business and Product Development Update
Business Wire - Wed Aug 06, 3:05PM CDT
--After Successful Phase 2b Results, Roclatan(TM) Phase 3 Enabling Activities in Progress
AERI: 21.90 (+0.15)
Aerie Pharmaceuticals, Inc. Receives Health Canada "No Objection Letter" to Commence Phase 3 Registration Trial of Rhopressa(TM) in Patients with Glaucoma in Canada
Business Wire - Thu Jul 24, 6:31AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that it has received a No Objection Letter ("NOL"
from Health Canada to conduct a Phase 3 registration trial of Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension in Canada. The study, named "Rocket 3," is designed to evaluate safety and tolerability of Rhopressa(TM) in patients over 12 months and is part of a broad Phase 3 program being conducted by Aerie. The Company recently announced the commencement of two Phase 3 trials in the United States, "Rocket 1" and "Rocket 2," which are focused on demonstrating non-inferiority of IOP lowering for Rhopressa(TM) compared to timolol, the most widely used comparator in registration trials for glaucoma. Aerie anticipates total enrollment of approximately 1,300 patients in the three Phase 3 trials of Rhopressa(TM). AERI: 21.90 (+0.15)
Aerie Pharmaceuticals to Announce Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 6, 2014
Business Wire - Wed Jul 23, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced today that its second quarter 2014 financial results will be released after the market closes on Wednesday, August 6, 2014. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.
AERI: 21.90 (+0.15)
Aerie Pharmaceuticals Initiates Phase 3 Registration Trials of Rhopressa(TM), Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma
Business Wire - Mon Jul 14, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on July 11, dosing commenced of the first patients enrolled in the Company's Phase 3 registration clinical trials of Rhopressa(TM), a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Aerie anticipates total enrollment of approximately 1,300 patients in three Phase 3 registration trials of Rhopressa(TM). The trials will measure efficacy over three months and safety over 12 months. The primary efficacy endpoint of the trials will be to demonstrate non-inferiority of IOP lowering for Rhopressa(TM) compared to timolol. Timolol is the most widely used comparator in registration trials for glaucoma. There will be two trials conducted in the United States, named "Rocket 1" and "Rocket 2," and one safety-only study in Canada, named "Rocket 3."
AERI: 21.90 (+0.15)
Executive Appointments and Technical Updates - Analyst Notes on Aeri Pharmaceuticals, DaVita, Prana Biotechnology, Raptor and Avanir Pharmaceuticals
PR Newswire - Mon Jul 14, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Aeri Pharmaceuticals, Inc. (NASDAQ: AERI), DaVita HealthCare Partners Inc. (NYSE: DVA), Prana Biotechnology Ltd. (NASDAQ: PRAN), Raptor Pharmaceuticals Corp. (NASDAQ: RPTP) and Avanir Pharmaceuticals (NASDAQ: AVNR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4726-100free.
AVNR: 11.80 (+0.01), DVA: 75.67 (+0.17), RPTP: 10.54 (-0.05), AERI: 21.90 (+0.15), PRAN: 1.96 (-0.01)
Aerie Pharmaceuticals, Inc. (AERI) in Focus: Stock up 8.37% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 7:44AM CDT
Aerie Pharmaceuticals, Inc. (AERI) was a big mover last session, as the company saw its shares rise over 8% on the day.
SGYP: 2.83 (-0.02), BCRX: 11.49 (+0.12), AERI: 21.90 (+0.15), OHRP: 7.07 (-0.26)
Weakness Seen in TherapeuticsMD (TXMD): Stock Tumbles 8.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 7:34AM CDT
TherapeuticsMD has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the past one day
SGYP: 2.83 (-0.02), BCRX: 11.49 (+0.12), TXMD: 4.16 (+0.01), AERI: 21.90 (+0.15)
Strength Seen in TherapeuticsMD, Inc. (TXMD): Stock Shoots 32.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:44AM CDT
TherapeuticsMD, Inc. (TXMD) was a big mover last session, as the company saw its shares surge over 32% on the day.
SGYP: 2.83 (-0.02), TXMD: 4.16 (+0.01), AERI: 21.90 (+0.15), OHRP: 7.07 (-0.26)
Why Auxilium Pharmaceuticals (AUXL) Could Be Positioned for a Slump? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:32AM CDT
Auxilium Pharmaceuticals has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
SGYP: 2.83 (-0.02), BCRX: 11.52 (+0.15), AUXL: 30.97 (-0.15), AERI: 21.90 (+0.15)
IntelliPharmaCeutics International (IPCI) Crumbles: Stock Plunges by 13.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:30AM CDT
IntelliPharmaCeutics International has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
SGYP: 2.83 (-0.02), BCRX: 11.52 (+0.15), IPCI: 2.72 (unch), AERI: 21.90 (+0.15)
